Tonghua Dongbao Pharmaceutical Co., Ltd. (600867)

Tonghua Dongbao Pharmaceutical Co., Ltd. (600867)

The company is mainly engaged in Chinese and Western patent medicine, biological products and plastic building materials. It is a key high-tech enterprise of the Torch Program recognized by the Ministry of science and technology of the people's Republic of China. The company and its major shareholder, Dongbao group, have developed and launched a large number of national new drugs and competitive products, such as zhennaoning, Dongbao Gantai tablets, Naoxuekang tablets, etc. In the field of biopharmaceuticals, its product "Ganshulin" has filled the domestic gap, making China a country that can produce recombinant human insulin and glargine insulin after the United States and Denmark. Dongbao gene recombinant human insulin phase II expansion project, a national key support project for revitalizing the northeast old industrial base with a total investment of 350 million yuan, is in the process of introducing and installing foreign advanced equipment. The company has become one of the largest human insulin production bases in China.

Nature of Business

Hard capsules, tablets (containing hormones), granules, small volume injections, API (recombinant human insulin), bioengineering products (recombinant human insulin injection); Class II 6854 operating room, emergency room, diagnosis and treatment equipment and appliances;

Class II 6815 injection puncture instrument; Class III 6815 injection puncture instruments. The company is a large-scale pharmaceutical enterprise producing Chinese and Western patent medicines and biological medicines. It is one of the large-scale human insulin production bases in the world. Its leading products include recombinant human insulin API, recombinant human insulin injection, etc., as well as a series of famous and high-quality products such as "Tonghua" brand grape wine, "bofelice" environmental protection building materials, etc.

>> tungsten carbide rings silver